Overview

Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-center study to evaluate the accuracy, reliability and functionality of the Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) dose indicator in adult subjects with moderate to very severe COPD over a 4-week Treatment Period.

Phase:

Phase 3

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Formoterol Fumarate
Glycopyrrolate